Trial · NCT00362232
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Composite Endpoint of Total Venous Thrombo Embolism (VTE) i.e.: Any Deep Vein Thromboembolism (DVT) (Proximal and/or Distal), Non Fatal Pulmonary Embolism (PE), Death of All Causes Per Protocol Population | Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.71 | Percentage of participants | ||
Composite Endpoint of Total Venous Thrombo Embolism (VTE) i.e.: Any Deep Vein Thromboembolism (DVT) (Proximal and/or Distal), Non Fatal Pulmonary Embolism (PE), Death of All Causes Per Protocol Population | Enoxaparin 30 mg Twice a Day (Bid) | 9.34 | Percentage of participants | ||
| Composite Endpoint of Total VTE i.e.: Any DVT (Proximal and/or Distal), Non Fatal PE, Death of All Causes Per Modified Intent to Treat Population. | Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.94 | Percentage of participants | ||
| Composite Endpoint of Total VTE i.e.: Any DVT (Proximal and/or Distal), Non Fatal PE, Death of All Causes Per Modified Intent to Treat Population. | Enoxaparin 30 mg Twice a Day (Bid) | 10.11 | Percentage of participants | ||
| Incidence of the Composite Endpoint Comprising Proximal DVT, Non-fatal PE and VTE- Related Death (Major VTE) Per Protocol Population of Major VTE | Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.09 | percentage of participants | ||
| Incidence of the Composite Endpoint Comprising Proximal DVT, Non-fatal PE and VTE- Related Death (Major VTE) Per Protocol Population of Major VTE | Enoxaparin 30 mg Twice a Day (Bid) | 1.47 | percentage of participants | ||
| Incidence of the Composite Endpoint Comprising Proximal DVT, Non-fatal PE and VTE- Related Death (Major VTE) Per Modified Intent to Treat Population of Major VTE. | Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.16 | percentage of participants | ||
| Incidence of the Composite Endpoint Comprising Proximal DVT, Non-fatal PE and VTE- Related Death (Major VTE) Per Modified Intent to Treat Population of Major VTE. | Enoxaparin 30 mg Twice a Day (Bid) | 1.98 | percentage of participants | ||
| Incidence of Symptomatic VTE (DVT, PE) Per Protocol Population. | Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.04 | percentage of participants | ||
| Incidence of Symptomatic VTE (DVT, PE) Per Protocol Population. | Enoxaparin 30 mg Twice a Day (Bid) | 1.48 | percentage of participants | ||
| Incidence of Symptomatic VTE (DVT, PE) Per Modified Intent to Treat Population. | Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.14 | percentage of participants | ||
| Incidence of Symptomatic VTE (DVT, PE) Per Modified Intent to Treat Population. | Enoxaparin 30 mg Twice a Day (Bid) | 1.88 | percentage of participants | ||
| Incidence of DVT (Proximal, Distal) Per Protocol Population. | Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.37 | percentage of participants | ||
| Incidence of DVT (Proximal, Distal) Per Protocol Population. | Enoxaparin 30 mg Twice a Day (Bid) | 8.66 | percentage of participants | ||
| Incidence of DVT (Proximal, Distal) Per Modified Intent to Treat Population. | Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.32 | percentage of participants | ||
| Incidence of DVT (Proximal, Distal) Per Modified Intent to Treat Population. | Enoxaparin 30 mg Twice a Day (Bid) | 8.97 | percentage of participants | ||
| Incidence of Symptomatic VTE During Follow-up Per Protocol Population. | Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 0.35 | percentage of participants | ||
| Incidence of Symptomatic VTE During Follow-up Per Protocol Population. | Enoxaparin 30 mg Twice a Day (Bid) | 0.11 | percentage of participants | ||
| Incidence of Symptomatic VTE During Follow-up Per Modified Intent to Treat Population. | Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 0.31 | percentage of participants | ||
| Incidence of Symptomatic VTE During Follow-up Per Modified Intent to Treat Population. | Enoxaparin 30 mg Twice a Day (Bid) | 0.21 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00362232/results